Champions Oncology Inc (CSBR) CEO Joel Ackerman Purchases 7,300 Shares
Champions Oncology Inc (OTCMKTS:CSBR) CEO Joel Ackerman acquired 7,300 shares of the business’s stock in a transaction on Friday, October 14th. The stock was acquired at an average price of $1.67 per share, with a total value of $12,191.00. Following the transaction, the chief executive officer now owns 1,035,466 shares in the company, valued at approximately $1,729,228.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Joel Ackerman also recently made the following trade(s):
- On Friday, October 7th, Joel Ackerman acquired 8,202 shares of Champions Oncology stock. The stock was acquired at an average price of $1.63 per share, with a total value of $13,369.26.
- On Friday, September 23rd, Joel Ackerman acquired 33 shares of Champions Oncology stock. The stock was acquired at an average price of $1.65 per share, with a total value of $54.45.
- On Wednesday, September 21st, Joel Ackerman acquired 5,000 shares of Champions Oncology stock. The stock was acquired at an average price of $1.66 per share, with a total value of $8,300.00.
Champions Oncology Inc (OTCMKTS:CSBR) traded down 0.60% during midday trading on Friday, hitting $1.65. The stock had a trading volume of 31,837 shares. Champions Oncology Inc has a 52 week low of $1.11 and a 52 week high of $5.46. The company’s 50-day moving average price is $1.66 and its 200 day moving average price is $2.56. The company’s market capitalization is $18.10 million.
Champions Oncology (OTCMKTS:CSBR) last issued its quarterly earnings results on Friday, September 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company earned $3.70 million during the quarter.
Champions Oncology Company Profile
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Stock Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related stocks with our FREE daily email newsletter.